Cantor Fitzgerald: 'We now expect apitegromab to have near complete market share'

March 19, 2026 2:11 PM

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and {REMOVEPT} price target on Scholar Rock (NASDAQ: SRRK).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found